MIT researchers in US advance Covid-19 vaccine into preclinical tests

Thursday, 23 April 2020
Drug Name : Recombinant Protein for Coronavirus Disease 2019 (COVID-19)

Therefore, you must look for some of the following details while ordering viagra no prescription online drugs from a Canada pharmacy. Kamagra Oral Jelly is offered as products of the soil enhanced gel sachets gathered in order viagra from india packs. Most physicians recommend cheapest cialis in UK because this drug is more effective than cialis or Cailis and also triggers minimum side-effects. If one of the parents has this disease, children has 50% to cialis lowest prices 60% of the genetic.

A research team at the Massachusetts Institute of Technology (MIT) in the US have advanced a Covid-19 vaccine candidate into preclinical tests in animal models.

Led by professor Christopher Love from MIT’s Koch Institute for Iterative Cancer Research, the team worked to develop preclinical materials for rapid progress of the candidate to clinical trials.

The candidate is said to be a subunit vaccine, which uses a small part of the virus’ protein to stimulate the immune system to detect the virus and prevent infection of host cells.

Commonly, subunit vaccines act by triggering antibodies that attach to and neutralise the virus, helping the body fight the virus.

While Love’s team is performing immunogenicity and formulation studies for this vaccine candidate, they are also working to create more vaccine candidates.

Simultaneously, the MIT team is focused on manufacturing an affordable vaccine at a large-scale, with an aim to produce billions of doses. The researchers collaborated with the Gates Foundation to work on towards their manufacturing goal.

Currently, the US Department of Health and Human Services is aiding Janssen Pharmaceuticals in developing 300 million vaccine doses.

[huge_it_slider id=”15″]The Love Lab is expediting the readiness of preclinical materials for manufacturing in order to meet the estimated requirement of billions of vaccine doses.

Love noted: “To reach the widest number of people, we need to be very intentional about incorporating in aspects of the manufacturability of a vaccine, even at the early stages of discovery.”

By concurrently working on the manufacturing process and animal testing, the team hopes to cut the time needed to transfer their processes to manufacturers.

In a statement, the team said: “By overlapping these stages of development, the whole process becomes streamlined, as manufacturers learn to work with materials, becoming better-prepared to produce vaccines at the scale needed once trials are completed.”

“COVID-19 Test Results: How Texting Makes it Easy for Patients to Access Lab Results from Epic”

Key Facts

News Category	Clinical Trials Other Product News Product Development
Company	Massachusetts Institute of Technology
Country	North America > United States of America